LJ
Therapeutic Areas
Zhifei Biological Products Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Recombinant Human Papillomavirus (HPV) Vaccine (Cecolin®) | Prevention of cervical cancer (HPV 16/18) | Approved |
| Recombinant COVID-19 Vaccine (ZF2001) | Prevention of COVID-19 | Approved |
| Recombinant Herpes Zoster Vaccine | Prevention of shingles | Phase 3 |
| 23-Valent Pneumococcal Polysaccharide Vaccine | Prevention of pneumococcal disease | Approved |
| Meningococcal Polysaccharide Vaccine (Groups A, C, Y, W135) | Prevention of meningococcal meningitis | Approved |
| Influenza Vaccine (Split Virion) | Prevention of seasonal influenza | Approved |
| DTaP-Hib Combined Vaccine | Prevention of diphtheria, tetanus, pertussis, Hib | Approved |
| Hepatitis B Vaccine | Prevention of Hepatitis B | Approved |
Leadership Team at Zhifei Biological Products
JR
Jiang Rensheng
Founder and Chairman of the Board
DW
Du Wenlin
Vice Chairman and General Manager (CEO)
WL
Wu Lizhi
Vice President
YS
Yang Shiming
Vice President
CX
Chen Xiaohong
Independent Director
HZ
Huang Zhen
Independent Director